News
CHICAGO -- Neoadjuvant nivolumab (Opdivo) plus chemotherapy significantly improved overall survival (OS) compared with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback